RDY
Dr. Reddy's Laboratories Ltd.

598
Mkt Cap
$11.69B
Volume
93,039.00
52W High
$16.17
52W Low
$12.26
PE Ratio
17.20
RDY Fundamentals
Price
$14.02
Prev Close
$14.05
Open
$14.01
50D MA
$14.17
Beta
0.40
Avg. Volume
1.21M
EPS (Annual)
$0.8029
P/B
2.90
Rev/Employee
$138,447.28
Loading...
Loading...
News
all
press releases
Dr. Reddy's Laboratories Breaks Above 200-Day Moving Average - Bullish for RDY
In trading on Wednesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $14.08, changing hands as high as $14.10 per share. Dr. Reddy's...
Nasdaq News: Markets·1d ago
News Placeholder
More News
News Placeholder
Frank Rimerman Advisors LLC Increases Stake in Dr. Reddy's Laboratories Ltd $RDY
Frank Rimerman Advisors LLC grew its holdings in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 72.3% during the 2nd quarter, according to the company in its most recent 13F...
MarketBeat·1d ago
News Placeholder
Vise Technologies Inc. Makes New Investment in Dr. Reddy's Laboratories Ltd $RDY
Vise Technologies Inc. acquired a new stake in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) during the second quarter, according to its most recent 13F filing with the Securities...
MarketBeat·2d ago
News Placeholder
What is Zacks Research's Forecast for RDY Q3 Earnings?
Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) - Zacks Research reduced their Q3 2026 EPS estimates for Dr. Reddy's Laboratories in a note issued to investors on Friday, November 14th. Zacks...
MarketBeat·3d ago
News Placeholder
Atria Investments Inc Boosts Stock Position in Dr. Reddy's Laboratories Ltd $RDY
Atria Investments Inc grew its position in shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 206.5% during the 2nd quarter, according to its most recent 13F filing with the...
MarketBeat·9d ago
News Placeholder
Migdal Insurance & Financial Holdings Ltd. Sells 20,000 Shares of Dr. Reddy's Laboratories Ltd $RDY
Migdal Insurance & Financial Holdings Ltd. lessened its position in Dr. Reddy's Laboratories Ltd (NYSE:RDY - Free Report) by 26.7% during the second quarter, according to the company in its most...
MarketBeat·11d ago
News Placeholder
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Zacks·13d ago
News Placeholder
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Zacks·24d ago
News Placeholder
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein...
Business Wire·29d ago
News Placeholder
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
Zacks·1mo ago

Latest RDY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.